Drug Trial Radar · NCT02063685
Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma
Last checked: Nov 20, 2026Latest source record: Jun 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
807
Actual
Start
Jul 2012
Primary completion
Dec 2021
Study completion Dec 2021
Sponsor
- Lead sponsor
- Fondazione Italiana Linfomi - ETSAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 14, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Recently, the availability of R has substantially changed therapeutic approach to FL patients, since its combination with chemotherapy has improved response rates, progression free survival (PFS) and overall survival (OS). Based on the results of recently completed randomized studies the standard treatment for patients with FL should consist of an initial therapy with R-CHOP combination followed by two-year maintenance with R. Although results of randomized trials confirmed that this approach results in an improved patients' outcome and made a step forward in the management of patients with FL, one important question that can be raised is if this approach is really needed for all patients with FL or if some of them could benefit from a reduced intensity treatment achieving the same results in terms of outcome and survival . This question is of particular interest for newly diagnosed patients for whom maintenance does not affect OS. More recent data demonstrated that the outcome of patients with FL can be further predicted by evaluating the quality of response to therapy studying minimal residual disease (MRD). This project addresses the objective of evaluating if combining clinical response assessed on FDG-PET scan and molecular response measured through MRD detection could permit to single out groups of patients at different risk of progression and to consequently modulate maintenance therapies, with the aim to provide clinicians a more rational use of the available diagnostic and therapeutic resources.
Conditions
- Follicular Non-Hodgkin's Lymphoma
Interventions
R-CHOP or R-bendamustineDrug
As induction therapy all patients will receive 6 courses of: Rituximab: 375 mg/m² day 1 iv Cyclophosphamide: 750 mg/m² day 1 iv Doxorubicin: 50 mg/m² day 1 iv Vincristine: 1.4 mg/m² day 1 iv (max dose 2mg) Prednisone: 100 mg day 1-5 os To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 21 days. or 6 courses of: Rituximab: 375 mg/m² day 1 iv Bendamustine: 90 mg/m² day 1 and 2 iv. To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 28 days.
ObservationDrug
not maintenance therapy and followed-up with MRD monitoring.
Maintenance weekly x4Drug
Four weekly doses of Rituximab (375 mg/m²). Rituximab could be repeated for MRD positive for a maximum of three courses
Ibritumomab Tiuxetan + MaintenanceDrug
single dose of (90)Y Ibritumomab Tiuxetan (0.4 mCi/kg). Following RIT patients will continue maintenance with Rituximab (375 mg/m² every 2 months) for a total of 11 infusions.
Standard MaintenanceDrug
Rituximab 375 mg/m² every 2 months for 2 years. Maintenance will have to be started no more than 12 weeks after the last induction chemoimmunotherapy infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFSTime frame: 12/31/2019
Locations
48 sites in 1 country. Site status is shown where the registry gives one.
Ospedale Civile Ss. Antonio E Biagio Di Alessandria - Alessandria (Al)
Alessandria, Italy
A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona _
Ancona, Italy
A.O. Universitaria Ospedale Consorziale Policlinico Di Bari
Bari, Italy
A.O. Ospedale Degli Infermi
Biella, Italy
A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna
Bologna, Italy
Pres.Ospedal.Spedali Civili Brescia
Brescia, Italy
Stabilimento "Perrino" - Brindisi -
Brindisi, Italy
Ospedale Armando Businco - Cagliari
Cagliari, Italy
A.O. Universitaria Ospedale Vittorio Emanuele Di Catania
Catania, Italy
Azienda Ospedaliera S. Croce E Carle Di Cuneo
Cuneo, Italy
A.O. Universitaria Careggi Di Firenze
Florence, Italy
A.O. Universitaria S. Martino Di Genova
Genova, Italy
Ematologia Ospedale Vito Fazzi
Lecce, Italy
Presidio Ospedaliero - Matera -
Matera, Italy
Azienda Ospedaliera Papardo
Messina, Italy
Irccs Ospedale Maggiore Policlinico Di Milano
Milan, Italy
Ospedale Ca' Granda-Niguarda
Milan, Italy
A.O. Universitaria Policlinico Di Modena
Modena, Italy
Irccs Istituto Nazionale Tumori Fondazione Pascale
Naples, Italy
A.O. Universitaria Maggiore Della Carita' Di Novara
Novara, Italy
Ospedale San Francesco
Nuoro, Italy
A.O. Universitaria Policlinico Giaccone Di Palermo
Palermo, Italy
A.O. "V. Cervello"
Palermo, Italy
A O Universitaria di Parma
Parma, Italy
IRCCS Policlinico S. Matteo
Pavia, Italy
Azienda Ospedaliera Di Perugia - Ospedale S. Maria Della Misericordia -
Perugia, Italy
Ospedale Civile Spirito Santo
Pescara, Italy
Ausl Di Piacenza
Piacenza, Italy
A.O. Universitaria Pisana
Pisa, Italy
Ospedale Bianchi - Melacrino - Morelli
Reggio Calabria, Italy
Ausl Di Rimini
Rimini, Italy
Universita' Degli Studi Di Roma 'La Sapienza'
Roma, Italy
Casa sollievo della Sofferenza
San Giovanni Rotondo, Italy
A.O. Universitaria Senese
Siena, Italy
A.O. Universitaria S. Giovanni Battista-Molinette Di Torino
Torino, Italy
Ospedale Ca Foncello
Treviso, Italy
A.O.Cardinale Panico Ematologia e centro trapianti
Tricase (LE), Italy
A.O. Universitaria S. Maria Della Misericordia Di Udine
Udine, Italy
Ospedale Di Circolo E Fondazione Macchi
Varese, Italy
Irst - Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori - Sede Di Meldola (Fc)
Meldola, Forlì Cesena, Italy
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.